Skip to content

SG&A at other companies

Eli Lilly logo
Eli LillyLLY
$2.93B+18.9%
Pfizer logo
PfizerPFE
$2.96B-2.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$647.7M+2.3%
Gilead Sciences logo
Gilead SciencesGILD
$1.45B+15.3%
AbbVie logo
AbbVieABBV
$3.58B+8.7%

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's SG&A?
WHWK (WHWK) reported SG&A of $6.29M in Q1 2026.
How has WHWK's SG&A changed year-over-year?
WHWK's SG&A decreased by 50.9% year-over-year, from $12.82M to $6.29M.
What is the long-term trend for WHWK's SG&A?
Over 3 years (2021 to 2025), WHWK's SG&A has grown at a 17.2% compound annual growth rate (CAGR), from $18.51M to $29.82M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.